

AstraZeneca Pharma India Limited

Regd. Office : Block N1, 12th Floor, Manyata Embassy Business Park, Rachenahalli, Outer Ring Road, Bangalore 560 045

Statement of unaudited results for the quarter and six months ended 30 September 2017

SI No.	Particulars	Rs in lakhs				
		3 months ended 30/09/2017 (Unaudited)	3 months ended 30/06/2017 (Unaudited)	3 months ended 30/09/2016 (Unaudited) (Refer Note 7)	6 months ended 30/09/2017 (Unaudited)	6 months ended 30/09/2016 (Unaudited) (Refer Note 7)
1	Revenue					
	a) Revenue from operations	16,425.83	12,846.58	13,940.64	29,272.41	28,027.15
	b) Other income	249.57	465.41	188.14	714.98	349.97
	Total revenue	16,675.40	13,311.99	14,128.78	29,987.39	28,377.12
2	Expenses					
	(a) Cost of materials consumed	312.40	547.77	305.72	860.17	625.55
	(b) Purchase of stock-in-trade	4,778.19	5,843.96	2,767.79	10,622.15	7,832.58
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	254.76	(1,877.19)	1,348.87	(1,622.43)	426.02
	(d) Excise duty	-	98.50	124.10	98.50	256.53
	(e) Employee benefits expense	3,640.19	3,493.88	4,656.49	7,134.07	8,776.59
	(f) Depreciation and amortisation expense	374.85	370.80	406.28	745.65	813.18
	(g) Selling, marketing and distribution	1,526.49	1,185.91	1,438.66	2,712.40	2,703.59
	(h) Other expenses	2,348.84	2,932.06	2,981.58	5,280.90	5,294.03
	(i) Finance cost	-	-	-	-	-
	Total expenses	13,235.72	12,595.69	14,029.49	25,831.41	26,728.07
3	Profit before exceptional and extraordinary items and tax (1-2)	3,439.68	716.30	99.29	4,155.98	1,649.05
4	Exceptional items	-	-	-	-	-
5	Profit before extraordinary items and tax (3+4)	3,439.68	716.30	99.29	4,155.98	1,649.05
6	Extraordinary items	-	-	-	-	-
7	Profit before tax (5+6)	3,439.68	716.30	99.29	4,155.98	1,649.05
8	Tax expense					
	- Current tax	698.77	152.60	19.04	851.37	308.67
	- Deferred tax	2.43	(16.03)	-	(13.60)	-
	Total tax expense	701.20	136.57	19.04	837.77	308.67
9	Profit for the period (7-8)	2,738.48	579.73	80.25	3,318.21	1,340.38
10	Other comprehensive income, net of income tax					
	A. Items that will not be reclassified to profit or loss	(9.43)	62.36	(60.54)	52.93	(154.54)
	B. Items that will be reclassified to profit or loss	-	-	-	-	-
	Total other comprehensive income, net of income tax	(9.43)	62.36	(60.54)	52.93	(154.54)
	Total comprehensive income for the period (9+10)	2,729.05	642.09	19.71	3,371.14	1,185.84
11	Paid-up equity share capital (Face value of Rs 2/- per equity share)	500.00	500.00	500.00	500.00	500.00
12	Earnings per equity share of Rs 2/- each (basic and diluted)	10.95	2.32	0.32	13.27	5.36



AstraZeneca Pharma India Limited
 Regd Office : Block N1, 12th Floor, Manyata Embassy Business Park,
 Rachenahalli, Outer Ring Road, Bangalore 560 045

Statement of assets and liabilities

(Rs in lakhs)

Sl.No.	Particulars	As at 30 September 2017 (Unaudited)
	ASSETS	
1	Non-current assets	
	(a) Property, plant and equipment	8,002.55
	(b) Capital work-in-progress	159.69
	(c) Financial Assets	
	(i) Investments	-
	(ii) Loans	148.67
	(iii) Other financial non-current assets	62.77
	(iv) Advance income tax (net)	2,368.65
	(d) Other non-current assets	131.99
	Sub-total - Non-current assets	10,874.32
2	Current assets	
	(a) Inventories	7,577.61
	(b) Financial Assets	
	(i) Trade receivables	7,408.86
	(ii) Cash and cash equivalents	15,137.55
	(iii) Bank balances other than (ii) above	25.96
	(iv) Loans	240.72
	(v) Other financial current assets	1,064.98
	(c) Other current assets	1,240.86
	Sub-total - Current assets	32,696.54
	TOTAL - ASSETS	43,570.86
1	EQUITY AND LIABILITIES	
	Equity	
	(a) Equity Share capital	500.00
	(b) Other Equity	21,104.13
	Sub-total - Shareholders' funds	21,604.13
	LIABILITIES	
	Non-current liabilities	
	(a) Financial Liabilities	
	(i) Other financial liabilities	39.44
	(b) Other non-current liabilities	-
	(c) Provisions	1,050.43
	Sub-total - Non-current liabilities	1,089.87
2	Current liabilities	
	(a) Financial Liabilities	
	(i) Trade payables	4,926.05
	(ii) Other financial liabilities	12,449.71
	(b) Other current liabilities	956.32
	(c) Provisions	1,995.54
	(d) Current tax liabilities	549.24
	Sub-total - Current liabilities	20,876.86
	TOTAL - EQUITY AND LIABILITIES	43,570.86




Notes:

- 1 The above statements of results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meetings held on 6 November 2017. The statutory auditors of the Company have carried out a limited review of this statement of results for the quarter ended 30 September 2017.
- 2 This Statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable. Beginning 1 April 2017, the Company has for the first time adopted Ind AS with a transition date of 1 April 2016.
- 3 The Company has identified 'Healthcare Segment' as its only reportable segment in accordance with the requirements of Ind AS 108, 'Operating Segments'. Accordingly no segment information has been provided.
- 4 As previously disclosed, by way of letter dated 1 March 2014, AstraZeneca Pharmaceuticals AB, the promoter of the Company had proposed a voluntary delisting of the Company's equity shares from the National Stock Exchange and the Bombay Stock Exchange. Such proposed delisting is subject to an on-going inquiry with SEBI and that inquiry has not yet been resolved. In any event, based on the passage of time, any potential future proposal for voluntary delisting of the Company would need to be conducted de novo.
- 5 The Statement does not include Ind AS compliant statement of results and statement of assets and liabilities for the previous year ended 31 March 2017 as the same is not mandatory as per SEBI's circular dated 5 July 2016.
- 6 Previous period's figures have been regrouped to conform to the current period's presentation for the purpose of comparability.
- 7 The Ind AS compliant corresponding figures for quarter and six months ended 30 September 2016 have not been subjected to review. However, the Company's management has exercised necessary due diligence to ensure that such corresponding figures provide true and fair view of the Company's results.
- 8 Pursuant to the completion of all the formalities for the divestment of Meronem, previously referred to in the stock exchange intimations on August 24, 2016 and July 28, 2017, the Company has made its final sales of Meronem in the reporting periods, representing 15% to 17% of total sales.
- 9 The reconciliation of net profit reported in accordance with Indian GAAP to total comprehensive income in accordance with Ind AS is given below:

Particulars	3 months ended 30/09/2016	6 months ended 30/09/2016
(a) Net Profit as per previous GAAP (Indian GAAP)	78.66	1,135.47
Add/ (less): Adjustment for Ind AS		
Impact on provision of expected credit loss	(52.45)	5.68
Reversal of rent equalisation reserve	6.33	12.65
Reclassification of net actuarial (gain)/loss on defined benefit plan to other comprehensive income	60.54	154.54
Impact of Employee stock compensation plan	(19.40)	0.83
Others*	6.57	31.21
(b) Net profit after tax as per Ind AS	80.25	1,340.38
(c) Other comprehensive income net of income tax:		
Actuarial loss on defined benefit plan	(60.54)	(154.54)
(d) Total comprehensive income under Ind AS (b+c)	19.71	1,185.84

* Others mainly include adjustments on account of discounting of non-current security deposits, employee loans, fair value adjustment on equity investments etc.,

By Order of the Board of Directors
For AstraZeneca Pharma India Limited


Gagan Singh Bedi
Managing Director

Place: Bengaluru
Date: November 6, 2017



Astrazeneca Pharma India Limited
Regd. Office : Block N1, 12th Floor, Manyata Embassy Business Park, Rachenahalli, Outer Ring Road, Bangalore 560 045
Statement of unaudited results for the quarter and six months ended 30 September 2017

Sl No.	Particulars	Rs in lakhs		
		Quarter ended 30 September 2017 (Unaudited)	6 months ended 30 September 2017 (Unaudited)	Corresponding three months ended 30 September 2016 (Unaudited)
1	Total income from operations	16,675.40	29,967.39	14,128.78
2	Net profit/(loss) for the period from ordinary activities before tax	3,439.68	4,155.98	99.29
3	Net profit/(loss) for the period from ordinary activities after tax	2,738.48	3,318.21	80.25
4	Total comprehensive income for the period after tax	2,729.05	3,371.14	19.71
5	Equity Share Capital	500.00	500.00	500.00
6	Reserves (excluding revaluation reserves as shown in the balance sheet of previous year) (Refer Note 3)	-	-	-
7	Basic and diluted earnings per share before extraordinary items (of Rs 2 each)	10.95	13.27	0.32

- Note:
- The above is an extract of the detailed format of Quarterly Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015. The full format of the Quarterly Financial Results are available on the Stock Exchange websites.(www.nseindia.com, www.bseindia.com) and Company's website (www.astrazeneca.com/india).
 - This Statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable. Beginning 1 April 2017, the Company has for the first time adopted Ind AS with a transition date of 1 April 2016.
 - Pursuant to the exemption available vide SEBI Circular dated 05 July 2016, the line item-"Reserves (excluding Revaluation Reserves), as per Balance Sheet of the previous accounting year ended 31 March 2017" has not been disclosed.

By Order of the Board of Directors
For Astrazeneca Pharma India Limited


Gagan Singh Bedi
Managing Director

Place: Bengaluru
Date: November 6, 2017